Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05423197 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC

Name: 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC — clinical trial record (NCT05423197)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusWithdrawn

PhasePhase 2

SponsorAndrei Iagaru

Started2026-06

View on ClinicalTrials.gov ↗

The purpose of this study is to determine the diagnostic utility of 89Zr-panitumumab to identify metastatic lesion(s) in subjects with head and neck squamous cell carcinoma (HNSCC).

Amendment history 4 changes detected by DataLookout

2026-08-18

Withdrawn before enrolling

2026-08-18

Trial withdrawn: logistical issues

2026-08-18

Enrollment reduced: 60 → 0 participants

2026-08-18

Sponsor changed: Stanford University → Andrei Iagaru

Was~~Stanford~~ ~~University~~

NowAndrei Iagaru

Trial Details

NCT Number	NCT05423197
Lead Sponsor	Andrei Iagaru
Conditions	Head-and-neck Squamous Cell Carcinoma
Start Date	2026-06
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-17